Expression of Fas ligand and Caspase-3 contributes to formation of immune escape in gastric cancer

Table 2 Relationship between the expression of FasL , Caspase-3 in cancer cells of primary foci and clinicopathological features of gastric cancer

Clinicopathological features	n	FasL expression						Caspase-3 expression
		-	+	++	+++	PR(%)	P value	-	+	++	+++	PR(%)	P value
Age							0.318						0.414
< 50 years	33	13	7	6	7	60.61		21	3	3	6	36.36
≥ 50 years	80	39	17	14	10	51.25		55	13	4	8	31.25
Gender							0.548						0.514
Male	83	37	16	16	14	55.42		57	12	5	9	31.32
Female	30	15	5	7	3	50.00		19	4	2	5	36.37
Tumor size							0.035						0.802
< 4 cm	47	27	8	7	5	42.55		33	3	5	6	29.79
≥ 4 cm	66	25	13	16	12	62.12		43	13	2	8	34.84
Invasive depth							0.039						0.987
Above submucosa	26	16	4	4	2	38.46		18	3	3	2	30.76
Muscularis propria	34	16	6	8	4	52.94		22	6	0	6	32.35
Below subserosa	53	20	11	11	11	62.26		36	7	4	6	33.96
Metastasis							0.039					0.913
-	75	40	12	15	8	46.67		51	9	3	12	32.00
+	38	12	9	8	9	68.42		25	7	4	2	34.21
TNM staging							0.312					0.506
O	18	10	3	3	2	44.44		12	3	1	2	33.33
I	28	13	4	8	3	53.57		18	3	2	5	35.71
II	40	19	8	8	5	52.50		26	7	2	5	35.00
III	17	7	2	2	6	58.82		13	1	1	2	23.53
IV	10	3	4	2	1	70.00		7	2	1	0	30.00
Growth pattern							0.338						0.735
Mass	23	8	5	10	0	65.22		17	3	1	2	26.09
Nest	30	12	4	5	9	60.00		18	5	1	6	40.00
Diffuse	34	18	7	3	6	47.06		23	5	2	4	32.35
Lauren'sclassification							0.038						0.333
Intestinal type	36	12	7	13	4	66.67		27	3	1	5	25.00
Diffuse type	57	32	10	8	7	43.86		36	9	5	7	36.84
Mixed type	20	8	4	2	6	60.00		13	4	1	2	35.00
Histological classification							0.015						0.754
Differentiated	53	19	9	14	11	64.15		37	6	2	8	30.18
Undifferentiated	60	33	12	9	6	45.00		39	10	5	6	35.00

PR, positive rate.